|
|
||||||||||
|
J Am Coll Cardiol, 2003; 42:301-308, doi:10.1016/S0735-1097(03)00627-2 © 2003 by the American College of Cardiology Foundation |

,
,*
* Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, Texas, USA
Department of Veterans Affairs Medical Center, Dallas, Texas, USA
Baylor University Medical Center, Dallas, Texas, USA
Manuscript received November 25, 2002; revised manuscript received April 10, 2003, accepted April 14, 2003.
* Reprint requests and correspondence: Dr. Paul A. Grayburn, Director of Cardiology Research, Baylor Heart and Vascular Institute, 3500 Gaston Avenue, Dallas, Texas 75216, USA.
paulgr{at}baylorhealth.edu
OBJECTIVES: This study was undertaken to optimize echocardiographic parameters for successful gene delivery to the heart and to extend the method from adenoviral to plasmid deoxyribonucleic acid (DNA).
BACKGROUND: We have previously shown that ultrasound-targeted microbubble destruction can direct tissue expression of adenoviral transgenes to the heart. The optimal echocardiographic parameters for this technique have not been reported.
METHODS: Adenoviral or plasmid DNA encoding the luciferase reporter gene was incorporated into liposome microbubbles and infused intravenously into anesthetized rats. We systematically evaluated the effects of ultrasound parameters known to influence microbubble destruction, including electrocardiogram (ECG) triggering, ultrasound frequency, mode of ultrasound, and mechanical index, on gene expression in rat myocardium four days after treatment. In addition, gene expression in heart, liver, and skeletal muscle were compared between adenoviral and plasmid DNA.
RESULTS: Optimal ultrasound parameters for this technique include low-transmission frequency (1.3 MHz), maximal mechanical index, and ECG triggering to allow complete filling of the myocardial capillary bed by microbubbles. No difference was seen between ultraharmonics and power Doppler mode. Using adenoviral DNA, optimal ultrasound parameters yielded myocardial luciferase activity on the order of 104 relative light units/mg protein/min but with even higher liver activity. Plasmid DNA was expressed in rat myocardium at similar levels but without detectable liver expression.
CONCLUSIONS: Ultrasound-targeted microbubble destruction can be used to deliver adenoviral or plasmid DNA to the myocardium. This technique holds great promise in applying the rapidly expanding repertoire of gene therapies being developed for cardiac disease.
| ||||||||||||||
This article has been cited by other articles:
![]() |
D. L. Miller, M. A. Averkiou, A. A. Brayman, E. C. Everbach, C. K. Holland, J. H. Wible Jr, and J. Wu Bioeffects Considerations for Diagnostic Ultrasound Contrast Agents J. Ultrasound Med., April 1, 2008; 27(4): 611 - 632. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, Z. Wang, H. Ran, X. Li, Q. Yuan, Y. Zheng, J. Ren, L. Su, W. Zhang, Q. Li, et al. Experimental Research on Therapeutic Angiogenesis Induced by Hepatocyte Growth Factor Directed by Ultrasound-Targeted Microbubble Destruction in Rats J. Ultrasound Med., March 1, 2008; 27(3): 453 - 460. [Abstract] [Full Text] [PDF] |
||||
![]() |
A R Lyon, M Sato, R J Hajjar, R J Samulski, and S E Harding Gene therapy: targeting the myocardium Heart, January 1, 2008; 94(1): 89 - 99. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. J. Muller, H. A. Katus, and R. Bekeredjian Targeting the heart with gene therapy-optimized gene delivery methods Cardiovasc Res, February 1, 2007; 73(3): 453 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chen, J.-h. Ding, R. Bekeredjian, B.-z. Yang, R. V. Shohet, S. A. Johnston, H. E. Hohmeier, C. B. Newgard, and P. A. Grayburn Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology PNAS, May 30, 2006; 103(22): 8469 - 8474. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Vancraeynest, X. Havaux, A.-C. Pouleur, A. Pasquet, B. Gerber, C. Beauloye, P. Rafter, L. Bertrand, and J.-L. J. Vanoverschelde Myocardial delivery of colloid nanoparticles using ultrasound-targeted microbubble destruction Eur. Heart J., January 2, 2006; 27(2): 237 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yoshida, K. Ohmori, H. Takeuchi, K. Shinomiya, T. Namba, I. Kondo, H. Kiyomoto, and M. Kohno Treatment of Ischemic Limbs Based on Local Recruitment of Vascular Endothelial Growth Factor-Producing Inflammatory Cells With Ultrasonic Microbubble Destruction J. Am. Coll. Cardiol., September 6, 2005; 46(5): 899 - 905. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chapman, J. Windle, F. Xie, A. McGrain, and T. R. Porter Incidence of Cardiac Arrhythmias With Therapeutic Versus Diagnostic Ultrasound and Intravenous Microbubbles J. Ultrasound Med., August 1, 2005; 24(8): 1099 - 1107. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Dean Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals Am J Physiol Cell Physiol, August 1, 2005; 289(2): C233 - C245. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Dittmar, J. Xie, F. Hunter, C. Trimble, M. Bur, V. Frenkel, and K. C. P. Li Pulsed High-Intensity Focused Ultrasound Enhances Systemic Administration of Naked DNA in Squamous Cell Carcinoma Model: Initial Experience Radiology, May 1, 2005; 235(2): 541 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bekeredjian, P. A. Grayburn, and R. V. Shohet Use of ultrasound contrast agents for gene or drug delivery in cardiovascular medicine J. Am. Coll. Cardiol., February 1, 2005; 45(3): 329 - 335. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Weyman The year in echocardiography J. Am. Coll. Cardiol., January 7, 2004; 43(1): 140 - 148. [Full Text] [PDF] |
||||
![]() |
H-D Liang and M J K Blomley The role of ultrasound in molecular imaging Br. J. Radiol., December 1, 2003; 76(suppl_2): S140 - S150. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bekeredjian, S. Chen, P. A. Frenkel, P. A. Grayburn, and R. V. Shohet Ultrasound-Targeted Microbubble Destruction Can Repeatedly Direct Highly Specific Plasmid Expression to the Heart Circulation, August 26, 2003; 108(8): 1022 - 1026. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |